


Gastroparesis Awareness Month Motivates Recruitment for Clinical Trial

August marks Gastroparesis Awareness Month, and a clinical trial targeting symptoms of gastroparesis is currently enrolling study participants.

WASHINGTON, D.C., UNITED STATES, August 24, 2021 /EINPresswire.com/ -- August marks Gastroparesis Awareness Month, and a clinical trial targeting symptoms of gastroparesis is currently enrolling study participants in multiple clinic locations across the United States.

Gastroparesis (delayed stomach emptying) is characterized by symptoms that typically occur during and after eating a meal, including nausea, early fullness, unusual fullness, and abdominal pain.

The clinical study will assess the efficacy and safety of a new oral investigational (test) drug in selected adults with gastroparesis. The study physicians aim to determine whether the test drug may help to improve symptoms like nausea, abdominal pain, and feelings of fullness during and after eating. Potential participants can complete a brief, anonymous survey at www.thegpstudy.com to determine if they may be eligible for the study. Those who participate will receive study drug and study-related medical care at no cost.



The advertisement is a vertical banner with an orange top section and a white middle section. The top section features a DNA double helix graphic and the text 'SP STUDIES'. The middle section features a green awareness ribbon graphic and the text 'August is GASTROPARESIS Awareness Month'. The bottom section features a photograph of a man eating from a bowl, with a blue text box containing the text 'NAUSEA isn't something you can ignore.' Below the photograph is a blue wavy graphic, and at the bottom is a yellow button with the text 'GO TO TheGPstudy.com'. A small text box at the bottom left of the advertisement contains the text: 'A clinical trial for adults over the age of 18 with nausea, feeling of fullness and belly discomfort is enrolling now. See if you qualify.'

According to the International Foundation for Gastrointestinal Disorders (IFFGD), approximately 5 million people in the United States are affected by gastroparesis. The number of people with gastroparesis appears to be rising, but gastroparesis is poorly understood and often difficult to diagnose. In most people, the cause is unknown (termed “idiopathic”), but possible causes include diabetes, surgeries, some medications, and illnesses. Gastroparesis Awareness Month is intended to raise community awareness about the condition.

To learn more about this clinical trial currently enrolling, clinical trial site locations across the United States, or to view qualification details, please visit www.thegpstudy.com.

####

About SmartPharma LLC

SmartPharma was founded by pharmacists and specializes in strategic consulting for biotechnology and biopharmaceutical companies. SP studies is a wholly owned subsidiary of SmartPharma LLC and assists with identifying potential clinical trial participants for study participation. The pharmacists at SmartPharma have worked with products from proof of concept to FDA approval across a variety of therapeutic areas.

To learn more about SmartPharma and SPstudies, visit www.smartpharmainc.com.

Katie MacFarlane
SmartPharma LLC
+1 202-506-7585
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/549632652>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.